Abivax (AAVXF) Accumulated Expenses (2021 - 2025)

Abivax has reported Accumulated Expenses for 5 years, with the latest figure at -$2.6 million in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 52.99% year-over-year to -$2.6 million in Q4 2025; TTM through Dec 2025 was -$2.6 million, a 52.99% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 million, down 52.99% from the prior year.
• Accumulated Expenses was -$2.6 million for Q4 2025 at Abivax, up from -$2.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $59.1 million in Q4 2021, with the low at -$2.7 million in Q3 2025.
• Average Accumulated Expenses over 5 years is $16.9 million, with a median of -$1.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses fell 15.0% in 2022, then sank 101.75% in 2023.
• Over 5 years, Accumulated Expenses stood at $59.1 million in 2021, then fell by 15.0% to $50.2 million in 2022, then tumbled by 101.75% to -$880118.8 in 2023, then tumbled by 94.51% to -$1.7 million in 2024, then tumbled by 52.99% to -$2.6 million in 2025.
• The last three Accumulated Expenses figures came in at -$2.6 million (Q4 2025), -$2.7 million (Q3 2025), and -$1.7 million (Q4 2024), per Business Quant data.